NCT00035971CompletedPhase 4
EVA: Evista Alendronate Comparison
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Eli Lilly and Company
- Locations
- 86
Study Overview
Brief Summary
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 50 Years to 80 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •50-80 years of age, inclusive
- •2 years since last menses
- •Dx femoral neck osteoporosis
- •No vertebral fractures
Exclusion Criteria
- •Poor candidate for study drugs
- •Hx of diseases affecting bone metabolism
- •Hx of breast/estrogen-dependent cancer
- •Current use of osteoporosis drug therapy
- •Hx/high risk of VTE
Investigators
Study Sites (86)
Loading locations...
Similar Trials
Unknown
Phase 3
Raloxifene in Treatment of Schizophrenia and Schizoaffective DisorderSchizophreniaSchizoaffective DisorderNCT01280305Sheba Medical Center200
Completed
Phase 4
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal OsteoporosisPostmenopausal OsteoporosisComplianceNCT01544894University of Valencia80
Completed
Phase 3
Trazodone Once a Day in Major Depression DisorderMajor Depressive DisorderNCT02086929Aziende Chimiche Riunite Angelini Francesco S.p.A364
Completed
Phase 2
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.SARS CoV 2 InfectionNCT05172050Dompé Farmaceutici S.p.A61
Active, not recruiting
Phase 3
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.Hormone Receptor Positive Breast CancerNCT01602380AstraZeneca462